Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Sakashita T
,
Yanagitani N
,
Koike S
,
Low SK
,
Takagi S
,
Baba S
,
Takeuchi K
,
Nishio M
,
Fujita N
,
Katayama R
.
???displayArticle.abstract???
The rearrangement of anaplastic lymphoma kinase (ALK) occurs in 3%-5% of patients with non-small cell lung cancer (NSCLC) and confers sensitivity to ALK-tyrosine kinase inhibitors (TKIs). For the treatment of patients with ALK-rearranged NSCLC, various additional ALK-TKIs have been developed. Ceritinib is a second-generation ALK-TKI and has shown great efficacy in the treatment of patients with both newly diagnosed and crizotinib (a first-generation ALK-TKI)-refractory ALK-rearranged NSCLC. However, tumors can also develop ceritinib resistance. This may result from secondary ALK mutations, but other mechanisms responsible for this have not been fully elucidated. In this study, we explored the mechanisms of ceritinib resistance by establishing ceritinib-resistant, echinoderm microtubule-associated protein-like 4 (EML4)-ALK-positive H3122 cells and ceritinib-resistant patient-derived cells. We identified a mechanism of ceritinib resistance induced by bypass signals that is mediated by the overexpression and activation of fibroblast growth factor receptor 3 (FGFR3). FGFR3 knockdown by small hairpin RNA or treatment with FGFR inhibitors was found to resensitize the resistant cells to ceritinib in vitro and in vivo. FGFR ligands from either human serum or fetal bovine serum were able to activate FGFR3 and induce ceritinib resistance. A detailed analysis of ceritinib-resistant patient-derived specimens confirmed that tyrosine-protein kinase Met (cMET) amplification induces ceritinib resistance. Amplified cMET counteractivated EGFR and/or Her3 and induced ceritinib resistance. These results reveal multiple ceritinib resistance mechanisms and suggest that ceritinib resistance might be overcome by identifying precise resistance mechanisms.
FIGURE 1. Anaplastic lymphoma kinase (ALK) amplification in the H3122 LR1 and LR5 and ALK L1198F mutation in the H3122 LR2 conferred intermediate and high resistance to ceritinib, respectively. A, C, G, The H3122 and H3122 LR cells were treated with the indicated concentrations of ALK inhibitors for 72 h. Calculated IC50 values are shown in (D). B, The ceritinib (LDK378)‐resistant H3122 cells were established by treating the parental H3122 (H3122 pt) cells with increasing concentrations of ceritinib over 6 months. E, The H3122 and H3122 LR1 and LR5 cells were treated with the indicated concentrations of ceritinib or crizotinib for 6 h. After incubation, the cells were lysed and analyzed by immunoblotting. F, Genomic DNA was extracted from five cell lines, and each relative ALK gene copy number was analyzed by qRT‐PCR. H, The Ba/F3 expressing EML4‐ALK‐WT or ‐L1198F cells were treated with the indicated concentrations of ceritinib for 4 h. After incubation, the cells were lysed and analyzed by immunoblotting.
FIGURE 2. Ceritinib resistance was induced by ligand‐dependent activation of FGFR3 in the H3122 LR3 cells. A, C, The H3122 and H3122 LR3 cells were treated with various concentrations of ceritinib with or without erlotinib (1 μM), cabozantinib (1 μM), or infigratinib (100 nM) for 72 h. B, The phosphorylation levels of 49 RTKs in the H3122 and H3122 LR3 cells were measured using an RTK array with cell lysates treated with or without 1 μM of ceritinib for 8 h. D, The H3122 LR3 cells were treated with ceritinib (1 μM) with or without infigratinib (100 nM) for 1–48 h. After incubation, the cells were lysed and analyzed by immunoblotting.
FIGURE 3. FGFR3 knockdown in H3122 LR3 cells restored sensitivity to ceritinib. A, Quantitative real‐time PCR was used to measure FGFR (FGFR1‐4) mRNA expression levels in the H3122 and H3122 LR3 cells. The H3122 LR3 mRNA expression levels (FGFRs/GAPDH) relative to those in the H3122 parental cells are shown in the bar graph. B, FGFR3 protein expression in the indicated shRNA‐infected H3122 LR3 cells was analyzed by immunoblotting. C, H3122 LR3 and shFGFR3 H3122 LR3 cells were treated with the indicated concentrations of ceritinib for 72 h. D, The H3122 LR3 and shFGFR3 H3122 LR3 cells were treated with 1 μM ceritinib for the indicated amount of time (0–2 h). After incubation, the cells were lysed and analyzed by immunoblotting. E, H3122 LR3 control cells and H3122 LR3‐sh374 cells were plated in RPMI‐1640 containing the indicated concentrations of human AB serum (Mediatech). Beginning the next day, they were cultured with 300 nM ceritinib for 0–96 h.
FIGURE 4. Combined treatment with alectinib and the FGFR inhibitor, zoligratinib, effectively resensitized H3122 LR3 cells to ceritinib in vivo. A, The H3122 LR3 cells were treated with various concentrations of alectinib with or without 1 μM of zoligratinib for 72 h. B, Schematic representation of the treatment schedule. After the tumors reached sizes of approximately 150 mm3, the mice were randomized by tumor size, and daily treatment with 50 mg/kg of alectinib with or without 50 mg/kg of zoligratinib was initiated. The tumor volumes were measured as 0.5 × length × width × height. The mean tumor volumes are shown in (C). *p < 0.05.
FIGURE 5. New ceritinib resistance mechanisms and therapeutic strategies to overcome them were identified. A diagrammatic representation of the identified ceritinib resistance mechanisms mediated by anaplastic lymphoma kinase (ALK) mutation (left) and bypass pathway activation resulting from FGFR3 or cMET overexpression.
Ahmad,
Mechanisms of FGFR-mediated carcinogenesis.
2012, Pubmed
Ahmad,
Mechanisms of FGFR-mediated carcinogenesis.
2012,
Pubmed
Azuma,
FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.
2014,
Pubmed
Beenken,
The FGF family: biology, pathophysiology and therapy.
2009,
Pubmed
Berger,
Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.
2018,
Pubmed
Cameron,
Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
2015,
Pubmed
Camidge,
Acquired resistance to TKIs in solid tumours: learning from lung cancer.
2014,
Pubmed
Ceccon,
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.
2015,
Pubmed
Cheng,
[Molecular pathology of lung cancer: key to personalized medicine].
2012,
Pubmed
Choi,
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
2010,
Pubmed
,
Echinobase
Dieci,
Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.
2013,
Pubmed
Doebele,
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
2012,
Pubmed
Engelman,
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
2007,
Pubmed
Friboulet,
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
2014,
Pubmed
Gainor,
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.
2015,
Pubmed
Gainor,
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
2016,
Pubmed
Harada,
Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.
2021,
Pubmed
Haura,
Erdafitinib Overcomes FGFR3-TACC3-Mediated Resistance to Osimertinib.
2020,
Pubmed
Isozaki,
Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
2016,
Pubmed
Jang,
Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.
2001,
Pubmed
Katayama,
Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
2015,
Pubmed
Katayama,
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
2012,
Pubmed
Katayama,
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
2011,
Pubmed
,
Echinobase
Katayama,
Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.
2009,
Pubmed
Katayama,
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
2016,
Pubmed
Katayama,
Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.
2018,
Pubmed
Kim,
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
2017,
Pubmed
Kogita,
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
2015,
Pubmed
Koivunen,
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
2008,
Pubmed
Makimoto,
Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
2019,
Pubmed
Mizuta,
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
2021,
Pubmed
Murase,
Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer.
2014,
Pubmed
Nakanishi,
The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
2014,
Pubmed
Okada,
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
2019,
Pubmed
Ou,
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
2011,
Pubmed
Raphael,
FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC).
2022,
Pubmed
Sasaki,
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
2011,
Pubmed
Sasaki,
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
2010,
Pubmed
Seto,
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
2013,
Pubmed
Shaw,
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
2009,
Pubmed
Shaw,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
2013,
Pubmed
Shaw,
Ceritinib in ALK-rearranged non-small-cell lung cancer.
2014,
Pubmed
Shaw,
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
2016,
Pubmed
Shimizu,
GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer.
2022,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Solomon,
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
2014,
Pubmed
Solomon,
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
2018,
Pubmed
Soria,
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
2017,
Pubmed
Sung,
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
2021,
Pubmed
Szymczyk,
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance.
2021,
Pubmed
Tanimoto,
Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.
2014,
Pubmed
,
Echinobase
Tsuji,
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.
2019,
Pubmed
Ware,
A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.
2013,
Pubmed
Yanagitani,
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
2020,
Pubmed
Yoshimura,
The expression and localization of fibroblast growth factor-1 (FGF-1) and FGF receptor-1 (FGFR-1) in human breast cancer.
1998,
Pubmed